Lenalidomide Stada

Lenalidomide, the active ingredient in Lenalidomide Stada, is an immunomodulatory drug (IMiD) presented as oral tablets for oral use. It is employed in the treatment of certain hematologic malignancies, including multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma, in adult patients.

GNH USA supplies Lenalidomide Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with strict quality assurance and regulatory compliance. The company ensures batch consistency, proper labeling, and adherence to EU pharmacopeial standards.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies.

Multiple myeloma: improves progression‑free survival and overall response rates in adult patients. Myelodysplastic syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission. Mantle cell lymphoma: contributes to disease control when combined with other therapies in relapsed or refractory cases.

Lenalidomide may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness reported by many patients. - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, often self‑limiting. - Rash: skin irritation or erythema. - Neutropenia: reduced neutrophil count requiring monitoring. - Thrombocytopenia: lowered platelet levels.

Serious or Rare Side Effects: - Venous thromboembolism: risk of deep‑vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly low neutrophils increasing infection risk. - Secondary primary malignancies: emergence of new cancers. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor laboratory parameters.

Pregnancy: contraindicated (Category X); avoid exposure. Thromboembolic risk: assess and consider prophylaxis. Renal impairment: dose adjustment may be required. Hematologic monitoring: regular CBC to detect cytopenias. Drug interactions: avoid concomitant use with strong CYP inducers without monitoring. Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Lenalidomide can interact with several medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Anticoagulants (warfarin): increased bleeding risk. - Live vaccines: risk of infection.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (aspirin): additive bleeding risk. - Other immunomodulatory drugs (e.g., thalidomide): enhanced toxicity. - P‑glycoprotein inhibitors (e.g., verapamil): may increase plasma levels.